Table 1.
Clinicopathological features of patients with stage II pancreatic adenocarcinoma (mean ± SD) n (%)
| Parameters | With vascular resection (n = 12) | Without vascular resection (n = 75) | P value |
| Age (yr) | 62.9 ± 11.0 | 62.9 ± 9.8 | 0.994 |
| Gender | 0.745 | ||
| Male | 7 (58.3) | 50 (66.7) | |
| Female | 5 (41.7) | 25 (33.3) | |
| Symptoms | |||
| Jaundice | 6 (50.0) | 55 (73.3) | 0.171 |
| Abdominal pain | 6 (50.0) | 35 (46.7) | 0.830 |
| Body weight loss | 6 (50.0) | 31 (41.3) | 0.573 |
| Anorexia | 3 (25.0) | 17 (22.7) | 1.000 |
| Signs | |||
| Anemic | 4 (33.3) | 38 (50.7) | 0.265 |
| Icterus | 6 (50.0) | 54 (72.0) | 0.178 |
| Abdominal tenderness | 3 (25.0) | 15 (20.0) | 0.707 |
| Albumin (g/dL) | 3.9 ± 0.6 | 3.7 ± 0.5 | 0.205 |
| Total bilirubin (mg/dL) | 6.8 ± 7.0 | 8.9 ± 7.1 | 0.333 |
| Pre-op biliary drainage | 0.573 | ||
| Yes | 6 (50.0) | 44 (58.7) | |
| No | 6 (50.0) | 31 (41.3) | |
| CEA (ng/mL) | 1.000 | ||
| ≤ 5 | 5 (62.5) | 36 (62.1) | |
| > 5 | 3 (37.5) | 22 (37.9) | |
| CA19-9 (U/mL) | 0.411 | ||
| ≤ 37 | 3 (33.3) | 13 (21.0) | |
| > 37 | 6 (66.7) | 49 (79.0) | |
| Operation time (min) | 473.9 ± 185.2 | 461.6 ± 110.4 | 0.826 |
| Blood transfusion (mL) | 396 ± 588 | 304 ± 590 | 0.618 |
| Tumor size (cm) | 3.6 ± 1.6 | 3.3 ± 1.4 | 0.526 |
| Lymph node metastases | 0.097 | ||
| Yes | 8 (66.7) | 65 (86.7) | |
| No | 4 (33.3) | 10 (13.3) | |
| Curability | 0.015 | ||
| Yes | 12 (100.0) | 48 (64.0) | |
| No | 0 (0.0) | 27 (36.0) | |
| Postoperative chemotherapy | 0.436 | ||
| Yes | 8 (66.7) | 41 (54.7) | |
| No | 4 (33.3) | 34 (45.3) | |
CA19-9: Carbohydrate antigen 19-9; CEA: Carcinoembryonic antigen.